Skip to main content

Advertisement

Table 1 Clinical characteristics of patients with CWS

From: Capsular warning syndrome: clinical analysis and treatment

 N = 72
Age, year (Mean ± SD);66.28 ± 7.90;
NIHSS score, median (IQR)8 (5–9)
Systolic pressure, mmHg (Mean ± SD)167.75 ± 22.76
Glucose, mmol/l (Mean ± SD)6.58 ± 1.81
Mean number of episodes, n (Mean ± SD)5.31 ± 2.22
Mean Duration, min (Mean ± SD)24.11 ± 11.21
ABCD2 score, median (IQR)5 (4–5)
Men, n (%)42 (58.33)
BMI ≥ 24 kg/m, n (%)16 (22.22)
Hypertension, n (%)52 (72.22)
Current Smoking, n (%)26 (36.11)
Current alcohol drinking, n (%)24 (33.33)
Diabetes, n (%)27 (37.50)
Hyperlipidemia, n (%)47 (65.28)
Family history of stroke, n (%)16 (22.22)
Medications use
 Antiplatelet, n (%)22 (30.56)
 Antihypertensive, n (%)31 (43.06)
 Lipid-lowering medications, n (%)36 (50.00)
Lacunar syndrome
 Pure motor syndrome, n (%)32 (44.44)
 Pure sensory syndrome, n (%)12 (16.67)
 Sensory motor syndrome, n (%)24 (33.33)
 Ataxic hemiparesis, n (%)4 (5.56)
Infarct location (58)
 Internal capsule, n (%)41 (70.69)
 Pons, n (%)5 (8.62)
 Striatum, n (%)2 (3.44)
 Thalamus, n (%)7 (12.07)
 Midbrain, n (%)3 (5.17)
Treatment
 Rt-PA, n (%)27 (37.50)
 Double Antiplatelet, n (%)30 (41.67)
 Single Antiplatelet (15)
 Aspirin, n (%)12 (16.67)
 Clopidogrel, n (%)3 (4.17)